Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Technologies Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock
SEATTLE , July 17, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a price
View HTML
Toggle Summary NanoString Technologies Announces Commencement of Public Offering of Common Stock
SEATTLE , July 16, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its
View HTML
Toggle Summary NanoString Technologies Provides Preliminary Revenue Results for Second Quarter 2018
- Second Quarter Product and Service Revenue Exceeds High End of Company Guidance - SEATTLE , July 16, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary
View HTML
Toggle Summary NanoString to Release Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 7, 2018
SEATTLE , July 09, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release second quarter 2018 financial results after the close of trading on
View HTML
Toggle Summary NanoString Establishes Netherlands Cancer Institute as a Center of Excellence for Digital Spatial Profiling
First Center of Excellence to Focus on Clinical Research and Biomarker Development SEATTLE , June 18, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the
View HTML
Toggle Summary NanoString Announces Collaboration with National Cancer Institute to Improve Cancer Immunotherapy Biomarker Discovery
NanoString’s PanCancer IO 360 panel will be used for characterization of immune activity and development of potentially predictive gene signatures in NCI-sponsored trials SEATTLE , June 04, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for
View HTML
Toggle Summary NanoString Highlights Record Number of nCounter-Based Abstracts at the 2018 Annual Meeting of the American Society of Clinical Oncology
More than 50 abstracts highlight the diverse capabilities of NanoString’s technologies in immuno-oncology, biomarker development and validation, and cancer characterization SEATTLE , May 31, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for
View HTML
Toggle Summary NanoString to Present at the 2018 UBS Global Health Care Conference
SEATTLE , May 15, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 2018 UBS Global Heath Care Conference
View HTML
Toggle Summary NanoString Technologies Releases Operating Results for First Quarter of 2018
SEATTLE , May 08, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter of 2018. First Quarter Financial Highlights Total revenue of
View HTML
Toggle Summary NanoString to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
SEATTLE , May 02, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Bank of America Merrill Lynch 2018
View HTML